Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 32: Cellular Pharmacology and Pharmacogenomics

Modulation of gene expression as mechanism of synergism between gemcitabine and pemetrexed in pancreatic cancer cell lines.

Romano Danesi, Alfredo Falcone, Elisa Giovannetti, Valentina Mey, Luca Marini and Mario Del Tacca
Romano Danesi
Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy, Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy, Eli Lilly, Firenze, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfredo Falcone
Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy, Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy, Eli Lilly, Firenze, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisa Giovannetti
Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy, Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy, Eli Lilly, Firenze, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Mey
Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy, Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy, Eli Lilly, Firenze, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Marini
Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy, Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy, Eli Lilly, Firenze, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Del Tacca
Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy, Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy, Eli Lilly, Firenze, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

3744

Gemcitabine is a pyrimidine analogue that inhibits ribonucleotide reductase (RR) as well as DNA synthesis and is now an established effective agent in the treatment of pancreatic cancer. The present study investigates whether pemetrexed, a new multitargeted antifolate that blocks folate metabolism and DNA synthesis, would be synergistic with gemcitabine against the MIA PaCa-2, PANC-1 and Capan-1 pancreatic cancer cell lines. Cells were treated with gemcitabine (1 h), and pemetrexed (24 h), alone or in sequence, and the analysis by the combination index demonstrated synergism mainly with the sequence pemetrexed-gemcitabine. To asses the role of drug metabolism on gemcitabine cytotoxicity, further studies were performed with inhibitors of the activating enzyme deoxycytidine kinase (dCK), and the inactivating enzymes 5′-nucleotidase (5′-NT), and cytidine deaminase (CDA). The crucial role of dCK in gemcitabine citotoxicity was confirmed by a ten-fold increase in IC50 by adding the dCK inhibitor 2′-deoxycytidine in all cell lines, while there was a modest increase in cytotoxicity by inhibition of 5′-NT and CDA, with respectively diethylpyrocarbonate and tetrahydrouridine. Cell cycle analysis by flow cytometry demonstrated that pemetrexed increased cell population in S phase (from 15.3 to 46.6% in MIA PaCa-2, from 10.6 to 80.1% in PANC-1 and from 46.4 to 63.2% in Capan-1 cells), which is the most sensitive phase of cell cycle to gemcitabine. Furthermore, all the pemetrexed-gemcitabine combinations significantly enhanced the occurence of apoptosis, as detected by fluorescence microscopy. Finally, quantitative RT-PCR analysis demonstrated that there was a correlation between the expression ratio dCK/RR and gemcitabine sensitivity; pemetrexed, at the IC50 level, significantly enhanced the expression of dCK(+227.9%, +86.0% and +135.5% in MIA PaCa-2, PANC-1 and Capan-1 cells, respectively), potentially facilitating gemcitabine activation. These data provide evidence that the combination of gemcitabine and pemetrexed displays schedule-dependent synergistic cytotoxic activity in vitro against pancreatic cancer cells, associated with favorable modulation of cell cycle, induction of apoptosis and enhanced expression of dCK.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Modulation of gene expression as mechanism of synergism between gemcitabine and pemetrexed in pancreatic cancer cell lines.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Modulation of gene expression as mechanism of synergism between gemcitabine and pemetrexed in pancreatic cancer cell lines.
Romano Danesi, Alfredo Falcone, Elisa Giovannetti, Valentina Mey, Luca Marini and Mario Del Tacca
Cancer Res April 1 2004 (64) (7 Supplement) 864;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Modulation of gene expression as mechanism of synergism between gemcitabine and pemetrexed in pancreatic cancer cell lines.
Romano Danesi, Alfredo Falcone, Elisa Giovannetti, Valentina Mey, Luca Marini and Mario Del Tacca
Cancer Res April 1 2004 (64) (7 Supplement) 864;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Enhancement of radiation response in human head and neck cancer cells in vitro and in vivo by the oral fluoropyrimidine anticancer agent (S-1).
  • Methylthioadenosine phosphorylase gene deletion and its role in drug efficacy in osteosarcoma.
Show more Experimental and Molecular Therapeutics 32: Cellular Pharmacology and Pharmacogenomics
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement